摘要
西罗莫司(免疫抑制剂)是一种新型免疫抑制剂,在临床上用于预防实体器官移植后的排斥反应。本文将影响其吸收、分布、消除的各种因素,如人口学特征、合并用药、血液生化指标、CYP3A5基因多态性、肝肾功能等,对西罗莫司群体药代动力学(PPK)参数的影响进行了综述。
Sirolimus that is a new immunosuppressive agent has been approved for preventing rejection after solid organs transplantation in clinical the setting. The article reviews some variability, e.g. demographic characteristics, incorporated drug, blood and biochemical indicator, the polymorphism of CYP3AS, hepat-and kidney function and other factors, that influence the parameters of sirolimus population pharmacokineties （PPK） through refering a great quantity internal and overseas literatures.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2010年第1期71-74,共4页
The Chinese Journal of Clinical Pharmacology
